tri-specific anti-Her1/Her3 Zybody (Zyngenia)

N/A

Report date: 2025/03/20 09:30:50

Base Information

Drug Nametri-specific anti-Her1/Her3 Zybody (Zyngenia)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugate +[4] 
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonistsReceptor tyrosine-protein kinase erbB-3 antagonists
TargetsReceptor tyrosine-protein kinase erbB-3Epidermal growth factor receptor erbB1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesZyngenia Inc
China Registration ClassN/A

Develop Information

Active CompaniesZyngenia Inc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A